There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Femasys (FEMY – Research Report) and BerGenBio AS (BRRGF – Research Report) with bullish sentiments.
Femasys (FEMY)
H.C. Wainwright analyst Emily Bodnar initiated coverage with a Buy rating on Femasys today and set a price target of $10.00. The company’s shares closed last Tuesday at $0.86, close to its 52-week low of $0.25.
According to TipRanks.com, Bodnar is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Femasys is a Strong Buy with an average price target of $9.67.
See today’s best-performing stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FEMY:
- Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
- Femasys completes EU MDR final audit
- Femasys Inc. EU MDR Final Audit Successfully Completed
- Femasys to showcase FemBloc, other products at AAGL meeting
- Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
